Medidata (NASDAQ:MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, is pleased to announce that Julie Iskow, executive vice president and chief technology officer, has been recognized by PharmaVOICE magazine as one of the 100 most inspiring people in the life sciences industry.

Julie Iskow was named to the prestigious list for her technical insight, transformational leadership and steadfast dedication to providing innovative technology that helps Medidata customers and partners worldwide accelerate hope for patients.

Since assuming her role at Medidata in 2015, Julie has leveraged her more than 20 years of experience in designing and developing cloud and SaaS applications, to lead the company’s technology efforts. She has succeeded in managing the growth of her team at Medidata collectively by almost 40%. Her department is responsible for the continued innovation and enhancement of the Medidata Clinical Cloud® — which has demonstrated unparalleled success in the market, including its widespread adoption, high customer retention rate and industry accolades. To date, the Medidata Clinical Cloud has supported approximately 13,000 studies and 3.7 million trial subjects, and 13 of the top 15 selling drugs globally were developed using Medidata technology.

“Julie is a transformational leader, whose technological insights and steadfast dedication to improving healthcare is helping Medidata combine cutting-edge tools and important data to help solve some of the most challenging problems for life-sciences companies,” says Taren Grom, editor of PharmaVOICE. “And her deep understanding for the need for greater collaboration to achieve innovation are just a few of the reasons why she is a 2017 PharmaVOICE 100 honoree.”

Recently named a 2017 Luminary by the Healthcare Businesswomen’s Association (HBA), Julie is helping Medidata to augment its cutting-edge solutions by incorporating important data and insights to solve big problems for global life sciences companies. At a time when clinical trial complexity and spend are at an all-time high, the importance of Julie’s role has never been more paramount.

This year’s distinguished honorees were nominated by thousands of PharmaVOICE readers and were selected for inclusion based on substantive accounts describing how they have inspired or motivated their colleagues, peers, and even competitors; their positive impact on patients, their organizations, and the industry at large; their innovative and game-changing strategies and thinking; their mentorship and guidance to the next generation of leaders; as well as their willingness to give their time and resources to their communities and philanthropic causes. Iskow becomes the thirteenth Medidata leader to be named to the PharmaVOICE 100.

“Julie is constantly looking for new and better ways to tackle today’s biggest challenges for the life sciences industry,“ said Mike Capone, Medidata’s chief operating officer. “She is incredibly deserving of this award, and we are thrilled that PharmaVOICE has recognized her passion and drive to deliver technology that will ultimately help the most important customer of all: the patient.”

About Medidata

Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.

About PharmaVOICE

PharmaVOICE: Published monthly, with the combined July/August PharmaVOICE 100 and November/December Year in Preview issues, PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of the executives who are shaping the direction of the dynamic and multifaceted life-sciences industry. PharmaVOICE reaches more than 41,000 BPA qualified subscribers and 60,000 users with its digital edition. PharmaVOICE’s unique horizontal editorial approach cuts across industry silos, providing a holistic overview of the life-sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics. Editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to- business relationships. PharmaVOICE’s multiple-perspective and in-depth original forums, feature articles, topics, and departments are audience-driven. PharmaVOICE provides executives with useful peer-to-peer insights on a broad range of business practices and topics to a wide range of life-science sectors.